PortfoliosLab logoPortfoliosLab logo
JANX vs. VALU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

JANX vs. VALU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Janux Therapeutics, Inc. (JANX) and Value Line, Inc. (VALU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, JANX achieves a 9.93% return, which is significantly higher than VALU's -8.55% return.


JANX

1D
-2.63%
1M
-2.38%
6M
10.65%
YTD
9.93%
1Y
-35.61%
3Y*
4.64%
5Y*
-14.10%
10Y*
ALL TIME*
-14.54%

VALU

1D
-0.70%
1M
-11.54%
6M
-7.03%
YTD
-8.55%
1Y
-5.12%
3Y*
-10.76%
5Y*
4.04%
10Y*
10.12%
ALL TIME*
6.85%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$12.19M$13.52M$15.80M
$103.64K$92.91K$101.65K

JANX vs. VALU - Yearly Performance Comparison


2026 (YTD)20252024202320222021
JANX
Janux Therapeutics, Inc.
9.93%-74.22%398.97%-18.53%-33.25%-41.97%
VALU
Value Line, Inc.
-8.55%-24.86%11.27%-1.94%10.35%42.08%

Correlation

The correlation between JANX and VALU is 0.16, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.16

Correlation (3Y)
Balances recent behavior with more history.

0.10

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.05

Correlation (All Time)
Calculated using the full available price history since Jun 11, 2021

0.06

The correlation between JANX and VALU shifts across timeframes, from 0.05 (5 years) to 0.16 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

JANX:

$925.13M

VALU:

$320.95M

EPS

JANX:

-$1.84

VALU:

$2.34

PS Ratio

JANX:

43.67

VALU:

9.50

Total Revenue (TTM)

JANX:

$21.61M

VALU:

$33.83M

Gross Profit (TTM)

JANX:

$8.44M

VALU:

$16.58M

EBITDA (TTM)

JANX:

-$134.03M

VALU:

$6.13M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

JANX vs. VALU — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

JANX
JANX Risk / Return Rank: 2626
Overall Rank
JANX Sharpe Ratio Rank: 2222
Sharpe Ratio Rank
JANX Sortino Ratio Rank: 2929
Sortino Ratio Rank
JANX Omega Ratio Rank: 2727
Omega Ratio Rank
JANX Calmar Ratio Rank: 2424
Calmar Ratio Rank
JANX Martin Ratio Rank: 2929
Martin Ratio Rank

VALU
VALU Risk / Return Rank: 3434
Overall Rank
VALU Sharpe Ratio Rank: 3838
Sharpe Ratio Rank
VALU Sortino Ratio Rank: 3232
Sortino Ratio Rank
VALU Omega Ratio Rank: 3333
Omega Ratio Rank
VALU Calmar Ratio Rank: 3636
Calmar Ratio Rank
VALU Martin Ratio Rank: 3333
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

JANX vs. VALU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Value Line, Inc. (VALU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


JANXVALUDifference
Sharpe ratioReturn per unit of total volatility

-0.34

Sortino ratioReturn per unit of downside risk

-0.14

Omega ratioGain probability vs. loss probability

0.97

1.00

-0.03

Calmar ratioReturn relative to maximum drawdown

-0.57

-0.26

-0.31

Martin ratioReturn relative to average drawdown

-0.77

-0.60

-0.18

JANX vs. VALU - Sharpe Ratio Comparison

The current JANX Sharpe Ratio is -0.50, which is lower than the VALU Sharpe Ratio of -0.16. The chart below compares the historical Sharpe Ratios of JANX and VALU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

JANX vs. VALU - Drawdown Comparison

The maximum JANX drawdown since its inception was -83.14%, which is greater than VALU's maximum drawdown of -77.54%. Use the drawdown chart below to compare losses from any high point for JANX and VALU.


Loading charts...

Drawdown Indicators


JANXVALUDifference

Max Drawdown

Largest peak-to-trough decline

-83.14%

-77.54%

-5.60%

Max Drawdown (1Y)

Largest decline over 1 year

-64.94%

-17.84%

-47.10%

Max Drawdown (3Y)

Largest decline over 3 years

-81.78%

-43.43%

-38.35%

Max Drawdown (5Y)

Largest decline over 5 years

-83.14%

-67.15%

-15.99%

Max Drawdown (10Y)

Largest decline over 10 years

-67.15%

Current Drawdown

Current decline from peak

-77.30%

-62.04%

-15.26%

Average Drawdown

Average peak-to-trough decline

-53.27%

-33.20%

-20.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

47.65%

7.71%

+39.94%

Volatility

JANX vs. VALU - Volatility Comparison

Janux Therapeutics, Inc. (JANX) has a higher volatility of 12.76% compared to Value Line, Inc. (VALU) at 11.32%. This indicates that JANX's price experiences larger fluctuations and is considered to be riskier than VALU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


JANXVALUDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.76%

11.32%

+1.44%

Volatility (6M)

Calculated over the trailing 6-month period

27.83%

21.04%

+6.79%

Volatility (1Y)

Calculated over the trailing 1-year period

74.08%

29.49%

+44.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

130.51%

60.81%

+69.70%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

129.97%

57.66%

+72.31%

Dividends

JANX vs. VALU - Dividend Comparison

JANX has not paid dividends to shareholders, while VALU's dividend yield for the trailing twelve months is around 3.95%.


PositionTTM20252024202320222021202020192018201720162015
JANX
Janux Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
VALU
Value Line, Inc.
3.95%3.32%2.23%2.24%1.91%1.86%2.52%2.73%3.65%3.67%3.44%4.37%

Financials

JANX vs. VALU - Financials Comparison

This section allows you to compare key financial metrics between Janux Therapeutics, Inc. and Value Line, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


JANX and VALU have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

JANX has higher volatility (12.76%) compared to VALU (11.32%). In terms of maximum drawdown, JANX dropped -83.14% vs VALU's -77.54%.

VALU currently has the higher Sharpe Ratio (-0.16 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for JANX and VALU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer